Aquestive Therapeutics Inc’s recently made public that its Chief Operating Officer Jung Cassie unloaded Company’s shares for reported $0.47 million on Oct 15 ’25. In the deal valued at $7.01 per share,67,575 shares were sold. As a result of this transaction, Jung Cassie now holds 240,771 shares worth roughly $1.37 million.
Then, Kraus Carl N sold 20,272 shares, generating $141,904 in total proceeds. Upon selling the shares at $7.00, the Chief Medical Officer now owns 282,475 shares.
Before that, Boyd Peter E. sold 10,000 shares. Aquestive Therapeutics Inc shares valued at $70,000 were divested by the insider at a price of $7.00 per share. As a result of the transaction, Boyd Peter E. now holds 268,323 shares, worth roughly $1.53 million.
A number of analysts have revised their coverage, including Cantor Fitzgerald’s analysts, who began to cover the stock in mid December with a ‘”an Overweight”‘ rating. Leerink Partners began covering AQST with “an Outperform” recommendation on May 10, 2024. Piper Sandler started covering the stock on April 11, 2024. It rated AQST as “an Overweight”.
Price Performance Review of AQST
On Tuesday, Aquestive Therapeutics Inc [NASDAQ:AQST] saw its stock jump 1.97% to $5.69. Over the last five days, the stock has lost -6.41%. Aquestive Therapeutics Inc shares have risen nearly 12.01% since the year began. Nevertheless, the stocks have risen 59.83% over the past one year. While a 52-week high of $7.55 was reached on 10/20/25, a 52-week low of $2.12 was recorded on 05/13/25.
Levels Of Support And Resistance For AQST Stock
The 24-hour chart illustrates a support level at 5.51, which if violated will result in even more drops to 5.32. On the upside, there is a resistance level at 5.81. A further resistance level may holdings at 5.93.
How much short interest is there in Aquestive Therapeutics Inc?
A steep rise in short interest was recorded in Aquestive Therapeutics Inc stocks on 2025-10-31, growing by 3.16 million shares to a total of 14.74 million shares. Yahoo Finance data shows the prior-month short interest on 2025-09-30 was 11.58 million shares. There was a rise of 21.43%, which implies that there is a positive sentiment for the stock.
The most recent change occurred on March 28, 2024 when Raymond James began covering the stock and recommended ‘”an Outperform”‘ rating along with a $7 price target.
